This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0272989X07308750v1 28/2/243    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Howard, D. H. Articles by Horowitz, M. M. Search for Related Content PubMed PubMed Citation Articles by Howard, D. H. Articles by Horowitz, M. M. Social Bookmarking                         What's this?

Use of Cost-Effectiveness Analysis to Determine Inventory Size for a National Cord Blood Bank

^* To whom correspondence should be addressed. E-mail: dhhowar{at}sph.emory.edu.

	Abstract

Background. Transplantation with stem cells from stored umbilical cord blood units is an alternative to living unrelated bone marrow transplantation. The larger the inventory of stored cord units, the greater the likelihood that transplant candidates will match to a unit, but storing units is costly. The authors present the results of a study, commissioned by the Institute of Medicine, as part of a report on the establishment of a national cord blood bank, examining the optimal inventory level. They emphasize the unique challenges of undertaking cost-effectiveness analysis in this field and the contribution of the analysis to policy. Methods. The authors estimate the likelihood that transplant candidates will match to a living unrelated marrow donor or a cord blood unit as a function of cord blood inventory and then calculate the life-years gained for each transplant type by match level using historical data. They develop a model of the cord blood inventory level to estimate total costs as a function of the number of stored units. Results. The cost per life-year gained associated with increasing inventory from 50,000 to 100,000 units is $44,000 to $86,000 and from 100,000 to 150,000 units is $64,000 to $153,000, depending on the assumption about the degree to which survival rates for cord transplants vary by match quality. Conclusion. Expanding the cord blood inventory above current levels is cost-effective by conventional standards. The analysis helped shape the Institute of Medicine’s report, but it is difficult to determine the extent to which the analysis influenced subsequent congressional legislation. Keywords: cost-benefit analysis; fetal blood; umbilical cord blood; bone marrow transplantation; hematopoietic stem cell transplantation. (Med Decis Making XXXX;XX:xx–xx)

First published on March 18, 2008, doi:10.1177/0272989X07308750

Medical Decision Making 2008;28:243.

A more recent version of this article appeared on March 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Gluckman and V. Rocha Cord blood transplantation: state of the art Haematologica, April 1, 2009; 94(4): 451 - 454. [Full Text] [PDF]

				S. Querol, G. J. Mufti, S. G.E. Marsh, A. Pagliuca, A.-M. Little, B. E. Shaw, R. Jeffery, J. Garcia, J. M. Goldman, and J. A. Madrigal Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? Haematologica, April 1, 2009; 94(4): 536 - 541. [Abstract] [Full Text] [PDF]

				M. Helfand and G. D. Sanders Policy Rounds: A New Series and a Call for Papers Med Decis Making, March 1, 2008; 28(2): 169 - 171. [PDF]